Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Rating of “Moderate Buy” by Brokerages

Abivax SA Sponsored ADR (NASDAQ:ABVX) has been assigned a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $128.7273.

A number of research analysts recently weighed in on ABVX shares. Citigroup reiterated an “outperform” rating on shares of Abivax in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, October 8th. BTIG Research boosted their target price on Abivax from $112.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, October 6th. Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a report on Thursday, November 6th. Finally, Citizens Jmp lifted their price target on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research report on Tuesday.

Abivax Stock Performance

Shares of ABVX stock opened at $114.94 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.77 and a current ratio of 7.86. The firm has a market capitalization of $8.96 billion, a price-to-earnings ratio of -66.44 and a beta of 0.48. Abivax has a one year low of $4.77 and a one year high of $138.49. The company has a 50 day moving average price of $108.73 and a 200 day moving average price of $71.42.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The firm had revenue of ($4.92) million for the quarter. Sell-side analysts anticipate that Abivax will post -2.83 EPS for the current year.

Hedge Funds Weigh In On Abivax

Several hedge funds and other institutional investors have recently made changes to their positions in ABVX. EverSource Wealth Advisors LLC lifted its stake in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares in the last quarter. First Horizon Corp purchased a new stake in Abivax during the 3rd quarter worth approximately $36,000. Hantz Financial Services Inc. acquired a new position in shares of Abivax in the 3rd quarter valued at approximately $52,000. Gordian Capital Singapore Pte Ltd acquired a new position in shares of Abivax in the 3rd quarter valued at approximately $76,000. Finally, Covestor Ltd purchased a new position in shares of Abivax during the 3rd quarter valued at approximately $96,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.